Repros Therapeutics Inc (RPRX) Short Interest Update

Repros Therapeutics Inc (NASDAQ:RPRX) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 852,002 shares, a drop of 34.8% from the January 12th total of 1,307,720 shares. Based on an average daily volume of 393,922 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.2% of the company’s shares are short sold.

A hedge fund recently bought a new stake in Repros Therapeutics stock. Kassirer Asset Management Corp bought a new position in Repros Therapeutics Inc (NASDAQ:RPRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 659,230 shares of the biotechnology company’s stock, valued at approximately $435,000. Kassirer Asset Management Corp owned approximately 1.67% of Repros Therapeutics at the end of the most recent quarter. Institutional investors own 13.58% of the company’s stock.

Shares of Repros Therapeutics (RPRX) traded down $0.01 during trading hours on Wednesday, hitting $0.67. The company had a trading volume of 251,700 shares, compared to its average volume of 473,590. The stock has a market cap of $26.50, a P/E ratio of -1.34 and a beta of 0.45. Repros Therapeutics has a 1-year low of $0.26 and a 1-year high of $1.33.

Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.24. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%. The business had revenue of $0.30 million for the quarter.

Separately, S&P Equity Research cut their price objective on Repros Therapeutics from $0.49 to $0.39 in a report on Monday, November 20th.

TRADEMARK VIOLATION NOTICE: “Repros Therapeutics Inc (RPRX) Short Interest Update” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply